Quantum-Si Stock Falls Below $1, Triggering Nasdaq Compliance Clock
Distressed
Company Background
Quantum-Si is a Branford, Connecticut-based proteomics company developing single-molecule protein sequencing technology. Its current commercial product, the Platinum Pro instrument, has been on the market for several years but has generated minimal revenue: $2.4 million for all of 2025, declining from $3.1 million in 2024, against a net loss of $101.3 million. The company's bet is on its next-generation Proteus platform, which it targets for commercial launch by year-end 2026 at a list price of $425,000 per instrument.
As of March 31, 2026, the company held $190.4 million in cash, cash equivalents, and marketable securities, which management states will sustain operations into the second quarter of 2028. First-quarter 2026 revenue was $258,000 on a net loss of $21.7 million. Full-year 2026 guidance calls for revenue of approximately $1.0 million — lower than 2025 — which management attributes to deliberate choices including embedding upgrade credits into Platinum Pro units sold during 2026 to ease the customer path to Proteus, as well as customers deferring purchases while awaiting the new platform.
The company has not been without turbulence in its asset base. In September 2025, it paid $11 million to exit a legacy New Haven, Connecticut office lease early. In September 2025, it also established an at-the-market equity offering program with Leerink Partners for up to $100 million in Class A shares. Share count has grown substantially, from roughly 147 million Class A shares at end-2024 to approximately 197 million by March 31, 2026.
What Was Disclosed
Nasdaq's Listing Qualifications Department notified Quantum-Si on July 23, 2026 that its Class A common stock has closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The notice has no immediate effect on trading — shares continue to trade on The Nasdaq Global Market under the symbol QSI — but it formally opens a compliance clock. Under Nasdaq Listing Rule 5810(c)(3)(A), Quantum-Si has 180 calendar days, until January 19, 2027, to regain compliance. To do so, the closing bid price must reach at least $1.00 per share for a minimum of 10 consecutive business days, though Nasdaq retains discretion to extend that window further.
If the company does not meet the January 19 deadline, it may seek a second 180-day extension by transferring its listing to The Nasdaq Capital Market, satisfying all applicable initial listing standards other than the bid price requirement, and providing written notice of its intent to cure — including through a reverse stock split if necessary. Should Nasdaq conclude compliance cannot be achieved within that additional period, it would issue a formal delisting notice. The company could then appeal to a Nasdaq Hearings Panel, though the filing cautions there is no assurance any such appeal would succeed. Quantum-Si said it intends to monitor its closing bid price and will consider all available options to regain compliance.
Why It Matters
The deficiency notice arrives five weeks after the company signed one of its most consequential leases. On June 18, 2026, Quantum-Si entered a 120-month agreement with Sterling City Science South Development, LLC for approximately 54,374 square feet of planned office, laboratory, and manufacturing space in San Diego at an initial monthly base rent of approximately $315,369, escalating by approximately 3% annually. The lease is structured to replace the company's existing San Diego space, which expires December 31, 2027. Rent payments are abated for the first 20 months after the expected September 2027 commencement date, and the landlord is contributing up to $17.1 million toward tenant improvements — terms that reduce the near-term cash burden materially, though they do not alter the decade-long commitment.
The financial picture behind the stock's slide is straightforward. Quantum-Si spent $101.3 million on a net basis in 2025 while collecting $2.4 million in revenue. Its 2026 guidance targets cash usage of up to $93 million against anticipated revenue of approximately $1.0 million. Management frames the revenue decline as intentional and temporary — a bridge strategy ahead of Proteus — and the $190.4 million cash position provides genuine operating runway. Still, the combination of a sub-$1 stock price, projected full-year revenue under $1 million, and a fresh 10-year real estate obligation concentrates attention on whether the Proteus launch can arrive on schedule and at sufficient commercial scale to change the company's trajectory before the compliance clock expires.
The active ATM offering shelf — up to $100 million in Class A shares via Leerink Partners — gives the company a potential tool for raising capital, though its practical utility depends on market conditions and the stock price. The primary compliance levers disclosed are stock price recovery and, if necessary, a reverse split to satisfy the $1.00 minimum bid requirement.